Dr. Guido Magni is a Managing Director at Versant EuroVentures. He is on the Board of Directors at Gensight Biologics SA, AM-Pharma Holding BV, Anabasis SRL, Aprea Therapeutics AB, Nouscom AG, PIQUR Therapeutics AG, Tarveda Therapeutics, Inc. and AM-Pharma BV. Dr. Magni was previously employed as an Independent Director by Biotie Therapies Oyj, Managing Partner by Aravis AG, an Independent Director by Adolor Corp., and Global Head-Medical Science Division by Hoffmann-La Roche, Inc. He also served on the board at Mosaic Biomedicals SL and Synosia Therapeutics AG. He received his doctorate degree from The American University of Rome and a doctorate degree from the University of Padua.